A Journey Towards Better Outcomes : The Evolution of Haploidentical HSCT from Ptcy to Αβ T-cell Depletion and Memory Addback in LMIC Context (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #829; 614; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "This study analyses haploidentical HSCT for IEI over 16 years at our centre, focusing on the transition from post-transplant cyclophosphamide (PTCy) to TCRαβ/CD19 depletion and the introduction of CD45RO+ memory T-cell add-back...With additional measures such as letermovir prophylaxis and virus-specific T-cell infusions, survival outcomes in low- and middle-income countries could approach that of high-income setting... The evolution from PTCy-based to TCRαβ/CD19-depleted haploidentical HSCT has significantly improved outcomes in children with IEI. Incorporating CD45RO+ memory T-cell add-back has further enhanced immune reconstitution without increasing GVHD risk. Although viral reactivation remains common, early immune recovery and effective antiviral therapy have reduced mortality."
Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease
|
|
Kavitha Ganesan; Minakshi Balwani; Nithya Seshadri; Vijayshree Muthukumar; Krithika Krishnakumar; Anuraag Reddy; Ramya Uppuluri; Revathi Raj
|